SISVEL-GROUP
23.6.2020 10:02:06 CEST | Business Wire | Press release
Sisvel Group, Arris and Ruckus Wireless today announced that they have entered into a Wi-Fi patent license agreement, managed by Sisvel International S.A. Arris and Ruckus Wireless thereby join the growing list of companies around the world that have access to patents licensed by Sisvel Group, including portfolios owned by Hera Wireless S.A., Aegis 11, Enact IP S.A., Fraunhofer IIS, Orange S.A., Koninklijke KPN N.V., Columbia University and Mitsubishi Electronic Corporation, which include patents related to the IEEE Wi-Fi Standards.
The agreement between Arris, Ruckus Wireless and Sisvel settles a dispute related to Arris’s and Ruckus Wireless’s alleged infringement of a number of Wi-Fi patents held by Hera Wireless and Aegis 11 and it provides for a worldwide patent license covering the sale and distribution of certain Wi-Fi enabled Arris and Ruckus Wireless products.
The Hera portfolio originated with Sanyo Electric of Japan and the patents comprising the Aegis portfolio originated with LG Electronics. The Hera and Aegis portfolios are comprised of over 100 and 140 patents respectively and claim a large international coverage with filings in over 40 countries.
“We are pleased to conclude an agreement with Arris and Ruckus Wireless that reflects the strength of Hera’s and Aegis’s patent portfolio, and we are very happy to welcome them to our ever-growing family of licensees.” said Nick Webb, Managing Director of Sisvel Spain S.L.
About Sisvel
Sisvel International S.A. is the holding company of the Sisvel Group. Sisvel is a world leader in fostering innovation and managing IP. The group identifies, evaluates and maximizes the value of IP assets for its partners around the world, providing firms with a revenue stream which can be reinvested in innovation for the generation of future revenues. Sisvel has more than 35 years’ experience in the management of successful patent portfolios, including those relating to audio compression standards (MP3 and MPEG audio), as well as broadcasting and digital terrestrial television standards maintained by the Digital Video Broadcasting Project. Sisvel operates patent pools and joint licensing programs in the fields of mobile communication, wireless local area networking 802.11, video coding, digital video broadcasting, recommendation engines and broadband access to data networks.
For additional information, please visit: www.sisvel.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200623005064/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB and Vår Energi Expand Digital Collaboration to Scale Well and Integrated Field Development Planning28.5.2026 13:47:00 CEST | Press release
Agreement supports Vår Energi’s ambition to reduce time to first oil, building on multi-discipline, collaborative well planning workflows that reduce cycle times from months to days Global energy technology company SLB (NYSE: SLB) today announced an expanded collaboration with Vår Energi to scale well planning and integrated field development planning across its Norwegian Continental Shelf operations. With collaborative well planning already reducing cycle times from months to days and integrated field development planning expected to support similar benefits, the expanded deployment is designed to support faster, more consistent decision-making as operators work to sustain production from mature offshore assets while managing increasing development complexity. As part of the expanded collaboration, Vår Energi is deploying the Delfi™ digital platform to connect exploration, subsurface evaluation, well planning, subsea design, field development planning, and production in a cloud-native
Kinaxis Convenes Global Supply Chain Leaders at Kinexions North America to Advance Agentic AI and Decision Orchestration28.5.2026 13:00:00 CEST | Press release
Annual conference brings customers, partners, and industry leaders together to explore how enterprises are turning decisions into coordinated action Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, is set to host Kinexions North America kicking off next week from June 1-3 at The Cosmopolitan of Las Vegas. The company’s flagship conference will bring together global supply chain, business and technology leaders for three days of product innovation, customer insights, and peer networking as Kinaxis continues to advance its focus on AI-driven decision making across the supply chain industry. This year’s event will spotlight how organizations are applying agentic AI and orchestration, moving beyond insight to execution, and increasingly from decisions to coordinated action. Speakers from global organizations including Merck, Bristol Myers Squibb, Unilever, British American Tobacco, Qualcomm, ExxonMobil, The Hershey Company, Scotts Miracle-Gro, and
Amadeus Redefines Travel Advertising to Help Brands Capture Demand Earlier28.5.2026 13:00:00 CEST | Press release
Developed in collaboration with Accenture, the AI-powered platform helps travel brands make smarter advertising decisions earlier and drive profitable demand through greater control, transparency, efficiency and performance. Amadeus today introduced the Amadeus Travel Advertising Platform at its Advertising Summit in Nice, France. Leveraging Accenture’s agentic framework for campaign execution, the platform outlines a new approach designed to help travel companies make faster, smarter advertising decisions based on where demand is forming — not just where it has already converted. Travel advertising has become increasingly complex, fragmented across channels and often driven by historical performance signals that arrive too late to capture emerging demand. As travelers plan trips across AI chatbots, search, social, metasearch, content platforms and OTAs long before booking, travel brands face rising acquisition costs and growing pressure to prove return on investment. The Amadeus Trave
Compass Pathways Elects Kathleen Tregoning to Board of Directors28.5.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the election of Kathleen Tregoning to its Board of Directors at the annual general meeting of shareholders. Ms. Tregoning is expected to serve on the Compensation and Leadership Development Committee and the Nominating and Corporate Governance Committee. She brings extensive experience guiding biopharmaceutical companies through periods of growth and transformation, with expertise spanning corporate strategy, external affairs, public policy and patient access. “With two successful Phase 3 trials meeting the primary endpoint, a transformative clinical profile for COMP360, and a rolling NDA submission and review now underway, Compass is strongly positioned to make our goal of securing an FDA approval a reality. Compass is entering a stage where experience in external engagement, public policy, and patient access matters more
Alzprotect Announces FDA Clearance of IND for AZP2006 (Ezeprogind®) in Progressive Supranuclear Palsy (PSP)28.5.2026 12:28:00 CEST | Press release
IND enables initiation of U.S. clinical development in PSP Alzprotect today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for AZP2006 (Ezeprogind®) for the treatment of Progressive Supranuclear Palsy (PSP). FDA clearance permits the Company to begin clinical development of AZP2006 in the United States. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526387210/en/ “FDA IND clearance is a pivotal step in our PSP program,” said Philippe Verwaerde, PhD, President & Chief science Officer. “We can now expand our clinical efforts in the U.S. to evaluate AZP2006’s potential to address PSP, a severe neurodegenerative disease with no approved disease-modifying therapies.” Dr. Artin Karapet, Chief Medical Officer, commented: “The FDA’s clearance of our IND for AZP2006 is a pivotal milestone, aligning U.S. and European regulatory pathways and enabling th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom